Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1818325 | 0.84 | KMT2A (0.39) | KMT2AFABP5FABP7EPHX2F10 | |
| SCHEMBL1819102 | 0.84 | FABP5 (0.43) | KMT2AFABP5FABP7EPHX2F10 | |
| SCHEMBL1821049 | 0.84 | KMT2A (0.39) | KMT2AFABP5FABP7EPHX2F10 | |
| SCHEMBL119453 | 0.84 | FABP5 (0.52) | KMT2AFABP5FABP7EPHX2F10 | |
| SCHEMBL13327274 | 0.83 | POLB (0.52) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL22397770 | 0.83 | POLB (0.52) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL14428331 | 0.83 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2F10 | |
| SCHEMBL6855032 | 0.83 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2F10 | |
| SCHEMBL7926629 | 0.83 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2F10 | |
| SCHEMBL28891959 | 0.83 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753862-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES | CSIR (ZA) | 2015-11-18 | — | — | EP | disclosed |
| US-20070275448-A1 | Methods For Obtaining Optically Active Epoxides And Vicinal Diols From Meso-Epoxides | CSIR (ZA) | 2007-11-29 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7220870-B2 | Hydrolytic kinetic resolution of cyclic substrates | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220870-B2 | Hydrolytic kinetic resolution of cyclic substrates | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-05-22 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | KMT2A 1997/4885FABP5 4837/4885FABP7 4861/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | KMT2A 1633/4885FABP5 4658/4885FABP7 4841/4885 |
| US-20070275448-A1 | Methods For Obtaining Optically Active Epoxides And Vicinal Diols From Meso-Epoxides | EPHX2, EPHX1, DHODH | KMT2A 2603/4885FABP5 2838/4885FABP7 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.